BRE AD01
Alternative Names: BRE-AD01; BxC-I17eLatest Information Update: 05 Oct 2023
At a glance
- Originator Brexogen
- Class Anti-inflammatories; Skin disorder therapies
- Mechanism of Action Exosome replacements; Immunosuppressants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Atopic dermatitis
Most Recent Events
- 05 Oct 2023 Brexogen plans a phase I trial for Atopic dermatitis (Treatment-experienced) (SC, Injection) in May 2024 (NCT06055374)
- 18 Apr 2023 Phase-I clinical trials in Atopic dermatitis (Treatment-experienced) in USA (SC) (NCT06055361)
- 07 Nov 2022 Brexogen plans a phase I trial for Atopic dermatitis in the US (Brexogen pipeline, November 2022)